Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

12.20
-0.6800-5.28%
Post-market: 12.13-0.0700-0.57%19:30 EDT
Volume:111.12K
Turnover:1.37M
Market Cap:298.95M
PE:-1.03
High:12.71
Open:12.70
Low:12.04
Close:12.88
52wk High:45.00
52wk Low:11.47
Shares:24.50M
Float Shares:10.79M
Volume Ratio:1.48
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.8281
EPS(LYR):-16.0562
ROE:-93.28%
ROA:-34.18%
PB:1.28
PE(LYR):-0.76

Loading ...

Lyell Immunopharma Provides Update on Safety Profile of Lyl273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - No Difference in GCC Car T-Cell Expansion With or Without Gi Prophylaxis

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Maximum Tolerated Dose Not yet Determined

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Additional Phase 1 Data and FDA Meeting Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Lyell Immunopharma presents Phase 1/2 safety, translational data for ronde-cel in relapsed/refractory large B-cell lymphoma at EHA 2026

Reuters
·
Jun 05

Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)

TIPRANKS
·
Jun 03

Lyell Immunopharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 03

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

GlobeNewswire
·
Jun 01

Lyell Immunopharma (LYEL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Lyell Immunopharma to present at H.C. Wainwright BioConnect investor conference

Reuters
·
May 12

Lyell Immunopharma Announces Participation in May Investor Conferences

GlobeNewswire
·
May 12

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
May 07

Lyell Immunopharma Q1 revenue misses, adjusted net loss narrows

Reuters
·
May 07

Lyell Immunopharma Q1 EPS $(1.10) Beats $(2.19) Estimate, Sales $2.000K Miss $4.400K Estimate

Benzinga Earnings
·
May 07

BRIEF-Lyell Immunopharma Q1 Net Income USD -24.153 Million

Reuters
·
May 07

Lyell Immunopharma Q1 Revenue USD 2 Thousand VS. Ibes Estimate USD 4.4 Thousand

THOMSON REUTERS
·
May 07

Lyell Immunopharma Q1 Operating Income USD -44.261 Million

THOMSON REUTERS
·
May 07

Lyell Immunopharma Q1 Operating Expenses USD 44.263 Million

THOMSON REUTERS
·
May 07

Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Dow Jones
·
May 07